Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I ...
Nasdaq15d
Corvus Pharmaceuticals Presents Promising Phase 1/1b Data for Soquelitinib in T Cell Lymphoma at 16th Annual T-Cell Lymphoma Forum
Corvus Pharmaceuticals reported positive Phase 1/1b trial data for soquelitinib in T cell lymphoma, showing significant anti-tumor activity. Corvus Pharmaceuticals, Inc. announced new findings ...
Corvus Pharmaceuticals: Now At Cruising Altitude
Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...
Business Insider15d
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
“The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of ...
Nasdaq23d
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
Dr. Rao previously presented preclinical data supporting the potential of soquelitinib in patients with ALPS. Other trial sites include Children’s Hospital of Philadelphia and Texas Children’s ...
Business Insider15d
Corvus announces presentation of data from Phase 1/1b trial of soquelitinib
Corvus Pharmaceuticals (CRVS) announced that additional data from the Company’s Phase 1/1b clinical trial of soquelitinib for the treatment of patients with T cell lymphoma is being presented at ...
Yahoo Finance15d
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from ...